This Biotech Startup Just Raised $105M to Extinguish Inflammation at the Source
Cour Pharmaceuticals’ nanoparticles reprogram the immune system to stop inflammation behind autoimmune disease. Three big pharma companies joined the startup’s Series A financing, which will fund clinical trials in type 1 diabetes and myasthenia gravis.
Source: medcitynews.com